Sugi Predict

Sugi Predict / Compounds / SCHEMBL6519571

SCHEMBL6519571

SCHEMBL6519571

Cc1c(-c2ccccc2)nc2ccc(-c3ccc(F)c(CO)c3F)cn12

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 2/20 0.50
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ NR1H4 Q96RI1 6/20 0.40
▸ SLC2A2 P11168 1/20 0.39
▸ SLC2A1 P11166 4/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ TOP2A P11388 1/20 0.39
▸ DHODH Q02127 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ CYP11B1 P15538 1/20 0.38
▸ CYP11B2 P19099 1/20 0.38
▸ ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6520541 0.91 NR4A2 (0.61) NR4A2CYP1A2CYP2C9CYP2C19NR1H4
SCHEMBL6521387 0.89 NR4A2 (0.51) NR4A2NR1H4SLC2A1NPC1RAB9A
SCHEMBL6527443 0.88 NR4A2 (0.47) NR4A2NR1H4SLC2A1NPC1RAB9A
SCHEMBL6524183 0.88 DHODH (0.44) CYP1A2CYP2C9CYP2C19NR1H4SLC2A2
SCHEMBL3431629 0.84 NR4A2 (0.46) NR4A2NR1H4SLC2A1
SCHEMBL6523534 0.82 SLC2A1 (0.39) NR4A2CYP1A2CYP2C9CYP2C19NR1H4
SCHEMBL3431442 0.81 NR4A2 (0.47) NR4A2CYP1A2CYP2C9CYP2C19NR1H4
SCHEMBL16208077 0.81 NR4A2 (0.65) NR4A2SLC2A2SLC2A1TOP2AMAPT
SCHEMBL6521811 0.79 TRPA1 (0.42) NR4A2NR1H4SLC2A1MAPTCYP11B1
SCHEMBL6523033 0.78 CYP11B1 (0.44) NR1H4SLC2A1NPC1RAB9ADHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262769-B1 POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-11-05 — — EP claimed
US-8507520-B2 Polysubstituted 2-aryl-6-phenylimidazo[1,2-A]pyridine derivatives, and preparation and therapeutic use thereof SANOFI (FR) 2013-08-13 — — US claimed
US-20110065745-A1 POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 — — US claimed
EP-2262769-B1 POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-11-05 — — EP disclosed
US-20110065745-A1 POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065745-A1 POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF JAK2, ABL1, REN NR4A2 1394/4885CYP1A2 34/4885CYP2C9 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.